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ABSTRACT
The binding of several rubromycin-based ligands to HIV1-reverse transcriptase was
analyzed using molecular docking and molecular dynamics simulations. MM-PBSA
analysis and examination of the trajectories allowed the identification of several
promising compounds with predicted high affinity towards reverse transcriptase
mutants which have proven resistant to current drugs. Important insights on the
complex interplay of factors determining the ability of ligands to selectively target
each mutant have been obtained.
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INTRODUCTION
HIV reverse transcriptases are multifunctional enzymes which use the virus single-
stranded RNA genome as template to build a double-stranded DNA which may later be
incorporated into the host’s genome. They are composed of two subunits: p66 acts both as
a DNA polymerase and as a RNAase which cleaves RNA/DNA hybrid molecules and p51
(whose sequence is equal to that of p66, but lacks the last 124 aminoacids) plays mostly
a structural role. Due to its crucial role in the virus life cycle, HIV reverse transcriptase
(RT) has been the target of several successful drug-developing efforts. These drugs may
be grouped in several classes based on their mechanism of action (thoroughly reviewed
in Jochmans, 2008; Sarafianos et al., 2009; Singh et al., 2010): nucleoside analogue RT
inhibitor (NRTI), like azidothymidine (Mitsuya et al., 1985) (the first successful drug
against HIV) act as an alternative substrate and block the synthesis of the viral DNA
due to their lack of a free 3’ OH- group; nucleotide-competing RT inhibitors (NcRTI)
like INDOPY-1 (Jochmans et al., 2006) bind the active site in an as-yet-undisclosed
manner; and non-nucleoside RT inhibitors (NNRTI) in contrast bind to the enzyme in a
hydrophobic pocket 10 A˚ away from the active site (Kohlstaedt et al., 1992; Ding et al., 1998)
and prevent the enzyme from attaining a catalytically competent conformation. Since
reverse transcriptases lack a proofreading ability, very high rates of mutation are observed
and mutants resistant to one or more drugs frequently arise. To decrease the probability of
selection of drug-resistant strains, a combination therapy including drugs with different
targets and modes of action is most often used in clinical practice. Still, newer drugs must
be continually developed to fight resistant strains.
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Rubromycins are a small class of compounds containing naphtoquinone and
8-hydroxyisocoumarin moieties (Brasholz et al., 2007). In 1990, β- and γ -rubromycin
were shown to inhibit HIV-1 reverse transcriptase (Goldman et al., 1990), although at
levels that were also toxic to human T lymphocytes. γ -rubromycin was later shown to
be an inhibitor of human telomerase (Ueno et al., 2000), fueling interest in its use as an
anti-cancer agent. The development of less toxic variants of these lead compounds has
long been prevented due to the difficulty of their laboratory synthesis, but several synthetic
routes to these interesting molecules have recently become available (Akai et al., 2007;
Rathwell et al., 2009; Wu, Mercado & Pettus, 2011; Wilsdorf & Reissig, 2014), enabling the
evaluation of many simpler derivatives as candidates for the inhibition of telomerase (Yuen
et al., 2013). As far as we could ascertain, no derivatives of γ -rubromycin with substitution
patterns as complex as those observed in the natural molecule have yet been synthesized.
As we envisage that such derivatives might afford higher selectivity towards selected
reverse-transcriptase mutants or more favorable pharmacokinetic properties, we decided
to evaluated several not-yet-synthesized γ -rubromycin derivatives using computational
docking and molecular dynamics simulations of the most promising candidates. The
results are compared to those of the commercially-available, 2nd-generation NNRTI drug
rilpivirine.
COMPUTATIONAL METHODS
All computations were performed in YASARA (Krieger et al., 2004) using the crystal
structure of the rilpivirine-inhibited HIV1 reverse transcriptase published by Das et
al. (PDB: 2ZD1) (Das et al., 2008). A double-mutant structure, (p66)K103N/(p66)Y181C
and a quadruple mutant (p51p66)M184I/(p51p66)E138K, were also generated to evaluate
the robustness of the ligand binding to reverse transcriptase variants with increased
resistance to NNRTIs: K103N is known to strongly reduce susceptibility to efavirenz
and nevirapine (Bacheler et al., 2001; Rhee et al., 2004; Eshleman et al., 2006; Zhang et
al., 2007; Melikian et al., 2014) and E138K has a similar effect towards rilpivirine, which
is increased by M184I (Kulkarni et al., 2012); Y181C reduces suceptibility to efavirenz,
etravirine and rilpivirine (Reuman et al., 2010; Tambuyzer et al., 2010; Rimsky et al., 2012).
γ -Rubromycin-based ligands (Fig. 1 and Supplemental Information 1) were docked to
the wild-type structure with AutoDock 4.2.3 (Morris et al., 2009) using default docking
parameters and point charges assigned according to the AMBER03 force field (Duan et
al., 2003). The highest scoring ligands and poses were selected for molecular dynamics
simulations. Initial structures for molecular dynamics simulations of mutant proteins were
generated from the corresponding ligand-bound wild-type structures through mutation
of the corresponding aminoacids. All simulations were run with the AMBER03 forcefield
(Duan et al., 2003), using a multiple time step of 1.25 fs for intramolecular and 2.5 fs
for intermolecular forces. Simulations were performed in cells 5 A˚ larger than the solute
along each axis (final cell dimensions 127.3× 102.6× 78.8 A˚), and counter-ions (88 Cl−
and 77 Na+) were added to a final concentration of 0.9% NaCl. In total, the simulation
contained approximately 106,500 atoms. A 7.86 A˚ cutoff was taken for Lennard-Jones
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Figure 1 Structures of the tested γ -rubromycin-based ligands. Substitution patterns in molecules 1–14;
17; 20–21 and 26–46 are shown in Supplemental Information 2 and Supplemental Information 1.
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forces and the direct space portion of the electrostatic forces, which were calculated using
the Particle Mesh Ewald method (Essmann et al., 1995) with a grid spacing <1 A˚, 4th
order B-splines and a tolerance of 10−4 for the direct space sum. Simulated annealing
minimizations started at 298 K, velocities were scaled down with 0.9 every ten steps for
a total time of 5 ps. After annealing, simulations were run at 298 K. Temperature was
adjusted using a Berendsen thermostat (Berendsen et al., 1984) based on the time-averaged
temperature, i.e., to minimize the impact of temperature control, velocities were rescaled
only about every 100 simulation steps, whenever the average of the last 100 measured
temperatures converged. Substrate parameterization was performed with the AM1BCC
protocol (Jakalian et al., 2000; Jakalian, Jack & Bayly, 2002). All simulations were run
for 30 ns. Differences in ligand binding energies between wild-type and mutant proteins
were evaluated using the MM-PBSA methodology (Srinivasan et al., 1998). Although
MM-PBSA is unable to afford accurate absolute binding energies and the high standard
deviation of MM-PBSA energies limits its ability to discriminate between ligands with
similar binding-affinities (Weis et al., 2006) to a protein, its application to the analysis
of the affinity of a single molecule to a series of protein mutants affords high quality
results (Moreira, Fernandes & Ramos, 2007; Martins et al., 2013), presumably due to
better cancellation of errors (as the effect of a point-mutation on a large protein is, in
relative terms, much smaller than that of a substitution in a small molecule). For each
snapshot (taken at 0.25 ns intervals from the last 15 ns of the simulation) we computed the
molecular mechanics energy of the protein–ligand complex, the electrostatic contribution
to solvation energy (using the Adaptive Poisson–Boltzmann Solver; Baker et al., 2001) and
nonelectrostatic contributions to solvation (with a surface-area-dependent term; Wang et
al., 2001). These computations were repeated for each snapshot for the ligand-free protein
and the protein-free ligand, to obtain an estimate of the average binding energy of each
ligand. Normal mode analysis computations were performed using the Webnm@ server at
http://apps.cbu.uib.no/webnma/home (Hollup, Salensminde & Reuter, 2005).
RESULTS
Computational docking allows the fast screening of a large number of candidate
ligands, which may afterwards be analyzed through more demanding computational
techniques in the search for suitable leads for further development and experimental
characterization. Out initial screen analyzed the docking performance of γ -rubromycin
derivatives with/without truncated rings, substitution of the oxygen atoms appended to
the spirocyclic ring and different substitution patterns around the rings. Twenty-six of the
tested γ -rubromycin-based ligands bind preferentially to an exposed pocket in subunit
p51 formed by the Glu89-His96 loop and the Pro157-Leu187 helix-turn-sheet motif. This
pocket lies very far away from the nucleic acid binding surface (Fig. 2), which completely
prevents this binding mode from competitively inhibiting the reaction mechanism.
This distant binding pocket might still affect the catalytic activity of the enzyme by
triggering a conformational change from the active “open” conformation (Ding et al.,
1998) to an inactive conformation. Since such transitions are usually too slow to be
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Figure 2 Preferential binding mode of ligand 28 to HIV reverse transcriptase, as computed with
AutoDock, with superposed DNA molecule taken from the DNA-bound HIV structure (PDB: 2HMI)
(Ding et al., 1998).
observed with molecular dynamics simulations, we analyzed the available vibrational
modes of HIV-1 reverse transcriptase using the efficient algorithm and simplified
force field described by Hinsen (1998). In this method, the protein is simulated as a
coarse-grained series of springs connecting every Cα with all other Cα atoms with
exponentially-decaying force-constants. Despite its conceptual simplicity, the computed
vibrational modes and vibration frequencies have been shown to correlate very well with
those observed in explicit molecular dynamics simulations. Furthermore, important
conformational changes can most frequently be explained by the first few non-trivial
vibrational modes, which enables its use in the location of allosteric transitions (Tama
& Sanejouand, 2001; Zheng & Brooks, 2005; Zheng, Brooks & Thirumalai, 2006; Zheng,
Brooks & Thirumalai, 2007; Rodgers et al., 2013; Sanejouand, 2013). Application of this
method to the catalytically active “open” conformation of HIV-1 reverse transcriptase
(PDB: 2HMI) (Ding et al., 1998) shows that inclusion of a coarse-grained representation of
γ -rubromycin in the proposed binding site does not affect the protein flexibility: indeed,
hardly any changes in vibrational modes are observed, as confirmed by the very high
correlation coefficients between the normal modes of ligand-bound and empty reverse
transcriptase, which always exceeding 0.9977. Figure 3 shows the contributions of each
aminoacid to the first six non-translational, non-rotational modes obtained by this
method, and clearly highlights the negligible contribution of the aminoacids lining this
proposed binding pocket to the overall flexibility of the enzyme.
Several γ -rubromycin-based ligands (11, 12, 18, 21, 30, 31, 33–46) may bind the
previously defined NNRTI-binding pocket with affinities exceeding those of this distant,
inactive, binding pocket. The most promising leads (Table 1) generally had (like the
NNRTI drug rilpivirine) a nitrile group appended to the ligand. The behavior of these
molecules in the reverse transcriptase binding pocket of wild-type and mutant reverse
transcriptase was then evaluated through 30 ns-long molecular dynamics simulations
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Figure 3 Relative contribution of each amino acid displacement to the first six non-trivial normal
modes of HIV-1 reverse transcriptase. (A) and (B) Modes 7 (blue), 8 (red) and 9 (green). C and
(D) Modes 10 (violet), 11 (light blue) and 12 (orange). The regions lining the proposed binding pocket
are highlighted in dark gray.
Table 1 Substitution patterns and AutoDock-computed binding energies of the best-scoring ligands to the previously characterized NNRTI
binding pocket. Only differences from the parent compound (γ -rubromycin) are shown. The binding energy of the drug rilpivirine, computed with
the same methods, amounts to−13.25 kcal mol−1. Data for all ligands is available as Supplemental Information 2.
Ligand: γ -rubromycin 46 36 27 45 13 38 37
R1= −COOCH3 –CH2OH









R11= –O–CH3 –CN –F –CN –CH2–CH3 –CN –Cl
Binding energy −12.95 −13.71 −13.72 −13.82 −13.82 −13.91 −14.25 −14.29
and compared to that of rilpivirine. The worst-scoring ligands towards the NNRTI
binding pocket were those where any of the rings had been removed, as well as the ones
where the oxygen at the R6 position was substituted by nitrogen or carbon. Surprisingly,
substitution of the =CH– at the R4 position by an isoelectronic =N– (ligand 32) also
led to a dramatic loss of binding affinity. Binding affinities of each ligand to wild-type
and mutant HIV-1 RT s were computed with the MM-PBSA methodology using the last
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Table 2 Binding affinity (average± standard error of the mean) of the best-scoring ligands to reverse-
transcriptase mutants, relative to the binding affinity of each ligand to the wild-type enzyme. Values
in kcal mol1. Negative values show stronger binding than observed to the wild-type protein.
K103N / Y181C E138K / M184I
Rilpivirine 1.6± 0.9 3.6± 0.8
γ-rubromycin 9.8± 1.1 0.3± 1.1
13 −6.7± 1.4 −16.8± 1.4
27 7.7± 1.4 −13.0± 1.2
36 10.3± 1.0 −7.1± 0.9
37 −4.0± 1.2 −5.2± 1.4
38 4.6± 1.0 −4.1± 0.9
45 −3.6± 1.0 −7.0± 1.2
46 −1.9± 1.2 −3.8± 1.0
15 ns of each molecular dynamics simulation (Table 2). This method, while not accurate
enough to produce reliable absolute binding free energies, has been shown to provide
good estimates of binding affinity trends provided that either the ligands or the protein
targets under comparison are very similar (Massova & Kollman, 2000). The computed
data for rilpivirine agree with the experimentally observed sensitivity of its binding to
E138K/M184I variants, and to the relative insensitivity of its effect on the presence/absence
of K103N or Y181C mutation, which supports the applicability of the MM-PBSA approach
to this system. Ligands 13, 27, 36 and 45 are computed to bind significantly stronger to
the rilpivirine-resistant E138K/M184I HIV1-RT variant than to the wild-type protein,
and may therefore be suitable lead compounds for further pharmaceutical developments
against rilpivirine-resistant strains. Further insight to the determinants of binding affinity
was obtained through close inspection of each simulation.
As observed in the crystal structure (Das et al., 2008), rilpivirine remains bound to
RT throughout the simulation through a large number of hydrophobic contacts and
two very stable hydrogen bonds with the backbone of Lys101, whether in the wild-type
or any of the tested mutants. Its high hydrophobicity strongly favor it to adopt a very
buried conformation and low solvent-accessible area throughout the simulation. The high
stability of the hydrogen bonds does not change in the mutated variants, but the total
number of close hydrophobic contacts between rilpivirine and the protein does become
smaller in the E138K/M184I mutant, which is consistent with the experimentally observed
lower affinity of this drug towards it (Singh et al., 2012), and the computed MM-PBSA
binding energy.
γ -rubromycin is a much larger and less flexible ligand than rilpivirine: as it binds to
the NNRTI binding patch, the methoxy-bearing end of γ -rubromycin remains in contact
with the solvent through its hydrophilic surface (Fig. 4), whereas the oxygen atoms in
its naphtoquinone moiety establish stable hydrogen bonds with Lys101 and Lys103. In
the K103N/Y181C mutant, γ -rubromycin becomes less exposed to the solvent, since the
shorter sidechain of Asn103 (compared to the wild-type Lys 103) forces the naphtoquinone
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Figure 4 γ -rubromycin (A) and rilpivirine (B) bound to wild-type HIV-1 reverse transcriptase. Snap-
shots were taken from random points in the last 15 ns of molecular dynamics simulations.
moiety of the ligand to penetrate deeper into the crevice in order to establish a stabilizing
hydrogen bond with Asn103. The buried conformation of γ -rubromycin removes the
methoxy group from its favored solvent-exposed environment leading to a binding
mode which is computed by MM-PBSA to be markedly less favored than observed in
the wild-type protein, but which remains stable due to the difficulty in breaking the large
number of favorable hydrogen bonds to Asn103 and Lys101. γ -rubromycin binding to
the E138K/M184I is very similar to the wild-type protein: hydrogen bonds between the
ligand and Lys101 and Lys103 are also present (though ca. 0.4 A˚ longer), and subtle cavity
rearrangements due to the loss of the ionic bridge between Lys101 and (p51)Glu138 (which
is mutated to a Lys) lead to the possibility of intermitent H-bonded interactions between
the carbonyl of Ile180 (or the sidechain of (p51)Thr139) and the naphtoquinone moiety.
The binding of ligand 13 to wild type RT differs more from that of γ -rubromycin than
would be expected from the very small difference in their structures (the single substitution
of a methoxy group in γ -rubromycin by an ethyl): since the ethyl group is less hydrophilic
than a methoxy, it initially tends to establish a hydrophobic interaction with the sidechain
of Val179, instead of protruding (like the methoxy group) in the direction of the solvent,
leading to a binding mode where the stabilizing hydrogen-bonds between the ligand
and the protein are due to Glu138 instead of Lys101. In contrast to what is observed in
the binding of γ -rubromycin to the K103N/Y181C, the replacement of the Lys-based
H-bonds does not lead to an unfavorable buried conformation of the ligand because, as
the simulation progresses, the interaction with Glu138 causes subtle changes in the local
environment which becomes more exposed to the solvent than originally: indeed, there is
in average one more water molecule near ligand 13 than near γ -rubromycin, leading to a
smaller desolvation penalty when 13 binds to the protein. Binding of 13 to the mutants is
strongly favored over binding to the wild-type due to the formation of hydrogen bonding
to the backbone of Ile180 (especially in E138K/M184I) and especially by the changes in the
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electrostatic component of ligand solvation caused by the presence of two intra-molecular
H-bonds in 13 when bound to the mutant proteins.
The sp3 hybridization in the acetyl-bearing carbon of the isocoumarin-moiety in 27
introduces a deviation from full planarity in that region of the ligand, which facilitates its
interactions with the Trp229 and Ty188 aminoacids on that end of the NNRTI-binding
cavity. Ligand 27 is found to bind much more favorably to the quadruple mutant
E138K/M184I (with a very large number of very short and stable hydrogen bonds with
Lys101, Lys103, Lys138 and Thr139) than to wild-type or K103N/Y181C, where the only
stable hydrogen bonds available are those with Glu138. The electrostatic component of the
solvation energy of 27 follows the opposite trend as the protein is changed from WT to
the mutants, but the smaller variation of this factor simply dampens the magnitude of the
change in binding affinities brought about by the variation in protein–ligand interactions.
Ligand 36 bears a fluorine atom in place of the methoxy group carried by γ -
rubromycin. Like ligand 27, 36 has higher affinity to the E138K/M184I mutant than
to either the wild-type and, especially, the K103N/Y181C mutant. The minute size of
the fluorine substituent allows Lys101 and Glu138 (which lie on opposite sides of the
crevice where the ligands bind) to approach each other and form a strong ionic bridge
which pushes the ligand further inside the cavity. This ionic bridge cannot form in the
E138K/M184I mutant, leading to a binding mode where the ligand is slightly more exposed
and strongly binds to Lys101, Lys103 and Lys 138. In the K103N/Y181C, the interactions
between ligand and protein are weaker due to the strong deviations from 180◦ in the
possible H-bonding partners in the binding cavity.
Ligands 37 and 38 bear a chlorine and a cyanide (respectively) in place of the fluorine
present on 36. The intermediate size of these substituents (relative to the fluorine in 36
and the methoxy in γ -rubromycin) leads to an intermediate degree of penetration in the
binding cavity, between those of 36 and in γ -rubromycin. As observed in most cases,
Lys101 is responsible for the most stable interaction between protein and ligand. No single
contribution is, however, determinant in the observed trend of binding affinity of 37 to
the proteins, as the correlation of total binding energies to either electrostatic components
of solvation or to protein–ligand interaction is insignificant: the overall effect is rather the
result of subtle interplay of the electrostatic component of solvation and the protein–ligand
interaction. Solvation effects, in contrast are determinant in the binding trends observed
for ligand 38, as the higher affinity to the M184I/E138K mutant is correlated to its much
smaller desolvation penalty, which is due to the considerable exposure of its nitrile group
to solvent when the entrance to the binding channel is not blocked by the Glu138-Lys101
ionic bond (Fig. 5).
Ligand 45 bears, like ligands 38 and 46, a nitrile group in the position occupied by a
methoxy in γ -rubromycin. It differs from 38 by the replacement of the acetyl substituent
of the isocoumarin by a hydroxymethyl and by switching the orientation of the lactone
group in isocoumarin from –O–C=O to O=C–O. The replacement of acetyl from
hydroxymethyl makes the isocoumarin end of 45 significantly smaller and less hydrophilic,
leading that end of the molecule towards the inside of the crevice and the nitrile-bearing
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Figure 5 Ligand 38 bound to wild-type (A and B), K103N/Y181C (C and D) and E138K/M184I (E
and F). Snapshots were taken from random points in the last 15 ns of molecular dynamics simulations.
As far as possible, the bonds depicted in the graphs have been highlighted with the same color in the
corresponding image (the exceptions are the C181 • • •OH hydrogen bond shown as the red line in D,
and the two hydrogen bonds between K101 backbone NH and nearby oxygen atoms in the inhibitor
shown as red and blue lines in F).
Bernardo and Silva (2014), PeerJ, DOI 10.7717/peerj.470 10/18
naphtoquinone portion of 45 to protrude from the other end of the cavity into the solvent.
The only H-bonds between ligand and protein now involve the backbone atoms of Lys101
and Glu138. These H-bonds weaken considerably in both mutants, but this destabilizing
effect is overtaken by sizable stabilizing effects due to favorable solvation, leading to overall
better binding to K103N/Y181C and (especially) E138K/M184I.
Other than the lack of H-bond donating ability in its isocoumarin moiety (due to the
replacement of its hydroxyl by a carbonyl), ligand 46 is identical to ligand 38. Unlike
ligand 38, its ability to bind the K103N/Y181C mutant is not inferior to its affinity to the
wild-type protein: the presence of a carbonyl instead of a hydroxyl allows it to accept a
hydrogen bond from Tyr183, which is able to rotate into position in the mutant due to
the smaller size occupied by Cys181 (compared to the original tyrosine present in the wild
type.)
We also performed molecular dynamics simulation of ligands 32 and 24 bound to the
NNRTI-binding pocket, as these ligands are ranked by AutoDock among the weakest
in affinity towards this binding site. These simulations are expected to shed light into
structural factors that disfavor binding to HIV-1 reverse transcriptase.
Ligand 24 (like the weakly-binding ligands 22, 23 and 26) lacks the spirocyclic scaffold
characteristic of rubromycins. The longer head-to-tail distance due to the opening of the
central acetal leads to a binding mode where the naphtoquinone moiety is buried inside
the enzyme in a position similar to that taken by isocoumarin in the other simulations
and the isocoumarin end becomes much more exposed to the solvent than observed for
naphtoquinone in the binding modes of the other ligands. This portion of the molecule
now remains continuously exposed to the solvent, significantly decreasing the number of
stable hydrophobic ligand-protein interactions. (Figures 6A and 6B.)
Ligand 32 differs from γ -rubromycin only in the replacement of the =CH group at
the R4 position by a nitrogen atom. This small isoelectronic change does not, however,
lead to very dramatic differences in dynamic behavior, as evidenced by the high similarity
of the resulting simulation to that of the original γ -rubromycin: Lys103 still maintains
a strong and stable interaction to the naphtoquinone moiety, and Lys101 now interacts
with the appended methoxy group in R11, rather than the –OH group in R8 (Fig. 6). The
weaker binding of 32 predicted by the docking analysis seems to be due mostly to the cost
of burying the polar=N– group away from the solvent, rather than on any large differences
of ligand-protein interactions.
INFLUENCE OF LIGAND BINDING ON PROTEIN
DYNAMICS
In the absence of NNRTI, reverse transcriptase may adopt either a compact structure
(Hsiou et al., 1996) or an open structure (Ding et al., 1998) which allows the binding of a
RNA template and the polymerization of DNA (Fig. 7). The binding of an NNRTI acts as
a “wedge” (Ivetac & McCammon, 2009) that further separates the catalytic triad (Asp110,
Asp185 and Asp186) from Met230, which is believed to be part of the primer-recognition
region. The same “wedge” effect is observed for all tested ligands bound to the NNRTI
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Figure 6 Ligands 24 (A and B), 32 (C and D) and γ -rubromycin (E and F) bound to wild-type reverse
transcriptase. Snapshots were taken from random points in the last 15 ns of molecular dynamics
simulations. As far as possible, the bonds depicted in the graphs have been highlighted with the same color
in the corresponding image (the exceptions are the I180 carbonyl • • • OH hydrogen bond shown as the
blue line in the B, and the hydrogen bond between K101 carbonyl and methoxy oxygen in γ -rubromycin
shown as a blue line in F).
binding pocket (Fig. 7 and Supplemental Information 6–16). The only instance where the
diagnostic Lys154-Asn255 and Glu67-Gln242 distances stably assume values as short as
those observed in the catalytically active conformation is observed in the simulation of the
K103N/Y181C mutant in the presence of ligand 46.
CONCLUSIONS
Our computational study confirms that γ -rubromycin-based ligands are able to bind
to HIV1-reverse transcriptase at the previously defined NNRTI-binding site, and
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Figure 7 Comparison between the catalytically active “open” conformation of HIV-1 reverse tran-
scriptase and the “extended” conformations obtained in the simulations. Side-view (A) and “top”-view
(B) of nucleic acid-bound reverse transcriptase (PDB: 2HMI) (Ding et al., 1998). Side-view (C and E) and
“top”-view (D and F) of a typical ligand-bound structure obtained in our simulations. The highlighted
distances can be used as “fingerprints” for the identification of catalytically competent conformations.
allowed the identification of ligands that are predicted to bind very strongly to RT
mutants which have shown high resistance towards other NNRTI compounds. The best
compounds (13, 27, 36 and 45) achieve selective binding to the highly resistant mutant
E138K/M184I through very subtle variations on the degree of exposure to solvent, and
on the number and strength of hydrogen bonds and hydrophobic interactions with
the protein. These molecules should therefore become good candidates in the quest for
suitable γ -rubromycin-based drugs.
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